ESOPHAGOGASTRODUODENAL FINDINGS IN PATIENTS WITH INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS (IPMNS)

Aims The association between intraductal papillary mucinous neoplasms (IPMNs) and extra-pancreatic malignancies is controversial. Our aim was to compare the esophagogastroduodenal findings among patients with IPMN and patients with no known IPMN.

Methods A cross sectional study comparing esophagogastroduodenoscopy (EGD) findings of 340 patients with IPMN, to 340 age- and gender-matched participants who underwent an EGD for similar clinical indications from 2004 through 2021. For each patient, only first EGD at the study period was included and new gastric and esophageal cancer, Barrett's esophagus, gastric and duodenal neuroendocrine tumors (NETs), gastrointestinal stromal tumors (GISTs), gastric adenomas and ampullary tumors were assessed.. Incidence of new gastric cancer among IPMN patients was also compared with data from the Israel National Cancer Registry (INCR) (updated to 2018).

Results In the IPMN group, new gastric cancer was diagnosed in 4/340 (1.2%), and esophageal cancer in 1/340 (0.3%). The incidence of gastric and esophageal cancer was similar in matched individuals, 5/340 (1.5%) and 0/340, respectively, (p>0.999). Also, the overall incidence of Barrett's esophagus, gastric and duodenal NETs, GISTs, gastric adenomas and ampullary tumors was not significantly differ between patients with IPMN and matched individuals. However, the incidence of gastric cancer was higher in patients with IPMN than expected using the INCR data (Standardized incidence ratio 31.39, p<0.001, CI 8.38-78.76).

Conclusions Patients with IPMN have a significantly higher incidence of gastric cancer than the average risk population in Israel. However, the incidence of esophagogastroduodenal findings is similar among patients with IPMN and patients who undergo EGD for different clinical indications.

 

MissingLinkText

Publikationsverlauf

Artikel online veröffentlicht:
14. April 2022